Skip to main content
. 2020 Nov 5;29(2):658–670. doi: 10.1016/j.ymthe.2020.11.001

Figure 5.

Figure 5

Effects of Neoadjuvant GMCI on T Cells in the Blood

Expression of T cell markers was assessed on baseline peripheral blood mononuclear cells (PBMCs) obtained from each patient prior to vector injection and compared to PBMCs obtained at the time of surgery (19–22 days after vector delivery). Paired t tests were applied to define the statistical significance (p value) of the change. (A) The percentages of specific types of T cells within the live PBMC population are plotted: upper left, CD3+ T cells; upper right, CD8+ T cells; lower left, CD4+ T cells; lower right, CD4+ regulatory T cells (CD4+/FOXP3+ cells). (B) The percentage of CD8+ T cells expressing specific activation/proliferation markers are plotted: upper left, CD38; upper right, HLA-DR; lower left, Ki67 (proliferation marker); lower right, 41BB (CD137). (C) The percentage of CD8+ T cells expressing specific inhibitory/activation markers are plotted: upper left, PD-1; upper right, CD39; lower left, CTLA-4; lower right, TIGIT.